Company to showcase new products and latest performance data for
next-generation sequencing applications during 2014 AGBT MeetingKAPA
hgDNA Quantification and QC Kit – A qPCR-based assay used to
assess the quality of FFPE material prior to NGS sample preparation.
The sample “quality score” provides a metric for optimizing DNA input,
library amplification and correlates with sequencing success. The KAPA
hgDNA Quantification and QC Kit is available now and compatible with
all Illumina and Ion Torrent NGS platforms.
KAPA Hyper Prep Kit – A second-generation DNA library
preparation kit that streamlines conventional library preparation
workflows and improves library yields, making it ideal for use in
applications with challenging samples, such as FFPE tissue or GC- and
AT-rich microbes. The KAPA Hyper Prep Kit is compatible with all
Illumina NGS platforms and will be commercially available in early Q2.
KAPA Stranded mRNA-Seq Kit – A RNA library preparation kit for
gene expression and copy number analysis applications. The kit
provides a streamlined workflow, 99 percent strandedness, and improved
detection of challenging GC-rich and low abundance transcripts. The
KAPA Stranded mRNA-Seq Kit is compatible with all Illumina NGS
platforms and will be commercially available in early Q2.
WILMINGTON, Mass. & MARCO ISLAND, Fla.--(BUSINESS WIRE)--
Kapa Biosystems, Inc., a leading supplier of reagents for the life
science market, today announced the launch of products that improve
performance and workflows for genomic research. The new suite of
products enables researchers to apply the latest next-generation
sequencing (NGS) technologies more effectively to millions of low
quality and challenging samples, such as formalin-fixed
paraffin-embedded (FFPE) tissue common in cancer profiling. Kapa
Biosystems and its customers will present data supporting the new
products during the 2014 Advances in Genome Biology and Technology
(AGBT) Meeting in Marco Island, Fla. on February 12-15.
“We remain focused on delivering innovative products that help unlock
the genetic code and provide insights into the transcriptome as we drive
towards a more holistic, systems biology understanding of genetics,”
said Brian Komorous, Director of Marketing at Kapa Biosystems. “With
these new products, we are building on the success of our DNA sequencing
solutions and expanding into RNA sequencing markets, with the goal of
improving performance and sequencing quality.”
Multiple Products to Accelerate DNA & RNA Research
Kapa Biosystems offers a portfolio
of high-performance reagents for use in PCR, qPCR, NGS, and
molecular diagnostics applications. The reagents contain novel enzymes
that confer significant performance advantages when compared to
traditional wild-type enzymes. Many of the products are optimized for
high-throughput workflows, and include pre-validated scripts using the
leading liquid handling automation platforms.
The latest NGS products offer significant workflow and performance
advantages over competitive offerings.
Later this year, Kapa Biosystems will continue to add to its RNA product
portfolio with additional pre-validated solutions using leading liquid
handling platforms for NGS applications.
Continued Commercial Growth and Expansion
Last month, Kapa
Biosystems announced several high-profile additions to its
management team, along with the relocation of its corporate and
international headquarters to larger facilities in Wilmington, Mass. and
Cape Town, South Africa respectively. Combined, these new locations
offer more than 25,000 square feet, which more than doubles the
company’s previous facility investment. These new hires and larger
facilities enable the company to scale enzyme production, quality
control and manufacturing capacity across its four business franchises,
increase headcount and expand R&D initiatives to better serve its
growing number of customers around the world.
About Kapa Biosystems
Kapa Biosystems is a life science reagents supplier that employs
proprietary, directed evolution technologies to optimize enzymes for
PCR, real-time PCR, next generation sequencing and molecular diagnostic
applications. Kapa Biosystems offers a portfolio of best-in-class
products containing novel enzymes that confer significant performance
advantages when compared to traditional wild-type enzymes. The company
is based in Wilmington, Massachusetts with a research, development and
manufacturing facility in Cape Town, South Africa. For more information,
please visit www.kapabiosystems.com
KAPA is a trademark of Kapa Biosystems. All other brands may be
trademarks of their respective holders.
Kapa Biosystems’ products are for Research Use Only; not for use in
For Kapa Biosystems
Andrew Noble, 415-722-2129
Source: Kapa Biosystems, Inc.